High hydrostatic pressure treatment generates inactivated mammalian tumor cells with immunogeneic features
- PMID: 20205624
- DOI: 10.3109/15476911003657414
High hydrostatic pressure treatment generates inactivated mammalian tumor cells with immunogeneic features
Abstract
Most of the classical therapies for solid tumors have limitations in achieving long-lasting anti-tumor responses. Therefore, treatment of cancer requires additional and multimodal therapeutic strategies. One option is based on the vaccination of cancer patients with autologous inactivated intact tumor cells. The master requirements of cell-based therapeutic tumor vaccines are the: (a) complete inactivation of the tumor cells; (b) preservation of their immunogenicity; and (c) need to remain in accordance with statutory provisions. Physical treatments like freeze-thawing and chemotherapeutics are currently used to inactivate tumor cells for vaccination purposes, but these techniques have methodological, therapeutic, or legal restrictions. For this reason, we have proposed the use of a high hydrostatic pressure (HHP) treatment (p >or= 100 MPa) as an alternative method for the inactivation of tumor cells. HHP is a technique that has been known for more than 100 years to successfully inactivate micro-organisms and to alter biomolecules. In the studies here, we show that the treatment of MCF7, B16-F10, and CT26 tumor cells with HHP >or= 300 MPa results in mainly necrotic tumor cell death forms displaying degraded DNA. Only CT26 cells yielded a notable amount of apoptotic cells after the application of HHP. All tumor cells treated with >or= 200 MPa lost their ability to form colonies in vitro. Furthermore, the pressure-inactivated cells retained their immunogenicity, as tested in a xenogeneic as well as syngeneic mouse models. We conclude that the complete tumor cell inactivation, the degradation of the cell's nuclei, and the retention of the immunogeneic potential of these dead tumor cells induced by HHP favor the use of this technique as a powerful and low-cost technique for the inactivation of tumor cells to be used as a vaccine.
Similar articles
-
High hydrostatic pressure inactivated human tumour cells preserve their immunogenicity.Cell Mol Biol (Noisy-le-grand). 2004 Jun;50(4):469-77. Cell Mol Biol (Noisy-le-grand). 2004. PMID: 15529756
-
Effect of extracorporal high hydrostatic pressure on tumor cell adherence and viability.Oncol Rep. 2004 Aug;12(2):369-73. Oncol Rep. 2004. PMID: 15254704
-
Prevention of metastases with a Mage-b DNA vaccine in a mouse breast tumor model: potential for breast cancer therapy.Breast Cancer Res Treat. 2005 May;91(1):19-28. doi: 10.1007/s10549-004-6454-7. Breast Cancer Res Treat. 2005. PMID: 15868428
-
Ex vivo- and in vivo-induced dead tumor cells as modulators of antitumor responses.Ann N Y Acad Sci. 2010 Oct;1209:109-17. doi: 10.1111/j.1749-6632.2010.05743.x. Ann N Y Acad Sci. 2010. PMID: 20958323 Review.
-
Immunology and breast cancer: therapeutic cancer vaccines.Breast. 2007 Dec;16 Suppl 2:S20-6. doi: 10.1016/j.breast.2007.07.004. Epub 2007 Aug 13. Breast. 2007. PMID: 17706425 Review.
Cited by
-
Analysis of clonogenic growth in vitro.Nat Protoc. 2021 Nov;16(11):4963-4991. doi: 10.1038/s41596-021-00615-0. Epub 2021 Oct 25. Nat Protoc. 2021. PMID: 34697469 Review.
-
Establishing safe high hydrostatic pressure devitalization thresholds for autologous head and neck cancer vaccination and reconstruction.Cell Death Discov. 2023 Oct 23;9(1):390. doi: 10.1038/s41420-023-01671-z. Cell Death Discov. 2023. PMID: 37872173 Free PMC article.
-
Exploiting the Immunogenic Potential of Cancer Cells for Improved Dendritic Cell Vaccines.Front Immunol. 2016 Jan 14;6:663. doi: 10.3389/fimmu.2015.00663. eCollection 2015. Front Immunol. 2016. PMID: 26834740 Free PMC article. Review.
-
Immunogenic cell death in cancer and infectious disease.Nat Rev Immunol. 2017 Feb;17(2):97-111. doi: 10.1038/nri.2016.107. Epub 2016 Oct 17. Nat Rev Immunol. 2017. PMID: 27748397 Review.
-
Tumor Cell-Based Vaccine Generated With High Hydrostatic Pressure Synergizes With Radiotherapy by Generating a Favorable Anti-tumor Immune Microenvironment.Front Oncol. 2019 Aug 28;9:805. doi: 10.3389/fonc.2019.00805. eCollection 2019. Front Oncol. 2019. PMID: 31555582 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous